NRx Pharmaceuticals (NRXP) to Release Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to be releasing its Q4 2025 results before the market opens on Friday, March 13th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.09) per share and revenue of $7.5250 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.77 on Friday. The company has a market capitalization of $56.41 million, a price-to-earnings ratio of -0.75 and a beta of 1.97. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84. The company’s 50-day moving average is $2.10 and its 200 day moving average is $2.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRXP. Geode Capital Management LLC raised its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the last quarter. Vanguard Group Inc. lifted its stake in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Two Sigma Investments LP lifted its stake in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter valued at about $994,000. Finally, State Street Corp boosted its holdings in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on NRXP shares. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. HC Wainwright increased their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Wednesday, February 18th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NRx Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $38.00.

More NRx Pharmaceuticals News

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year EPS forecasts and reiterated a Buy rating with a $45 price target, projecting material earnings growth from FY2026 through FY2029 (Q4‑2026: $0.06; FY2026: $0.13; FY2027: $1.23; FY2028: $3.18; FY2029: $5.06). This signals that at least one boutique analyst expects a strong recovery and significant upside vs. the current share price. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock
• Neutral Sentiment: Zacks Research moved NRXP from “strong sell” to “hold,” reducing one source of bearish pressure but not endorsing a buy — a modest signal that downside may be stabilizing but not yet reversed. Zacks upgrade coverage (TickerReport)
• Negative Sentiment: HC Wainwright trimmed its Q3‑2026 EPS estimate (from $0.04 to $0.03), a near-term downgrade that tempers some of the upbeat multi-year outlook and highlights potential short-term execution or timing risk. MarketBeat NRXP coverage (analyst notes)
• Negative Sentiment: Consensus still shows a current full-year loss (consensus ~($1.75) EPS), so HC Wainwright’s optimistic projections are aggressive and depend on successful product/commercial execution and milestone delivery; failure to meet milestones would keep downside risk elevated. MarketBeat NRXP consensus data

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.